Exome Asset Management LLC Sells 15,446 Shares of Guardant Health, Inc. $GH

Exome Asset Management LLC reduced its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 15.7% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 82,736 shares of the company’s stock after selling 15,446 shares during the quarter. Guardant Health comprises 4.0% of Exome Asset Management LLC’s portfolio, making the stock its 5th biggest holding. Exome Asset Management LLC’s holdings in Guardant Health were worth $7,642,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently made changes to their positions in GH. V Square Quantitative Management LLC acquired a new position in shares of Guardant Health during the 4th quarter valued at about $27,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of Guardant Health in the 4th quarter valued at approximately $31,000. Elyxium Wealth LLC acquired a new stake in Guardant Health in the 4th quarter worth approximately $35,000. Parallel Advisors LLC lifted its holdings in Guardant Health by 164.7% in the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after purchasing an additional 219 shares during the last quarter. Finally, Ascentis Independent Advisors acquired a new stake in Guardant Health in the 1st quarter worth approximately $38,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Price Performance

NASDAQ:GH opened at $145.47 on Tuesday. Guardant Health, Inc. has a one year low of $40.35 and a one year high of $174.08. The company has a fifty day moving average price of $140.40 and a 200 day moving average price of $112.25. The stock has a market cap of $19.29 billion, a P/E ratio of -42.91 and a beta of 1.59.

Insider Buying and Selling at Guardant Health

In related news, insider Chris Freeman sold 24,406 shares of Guardant Health stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $118.67, for a total transaction of $2,896,260.02. Following the sale, the insider directly owned 60,034 shares of the company’s stock, valued at $7,124,234.78. This trade represents a 28.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Meghan V. Joyce sold 10,000 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $126.98, for a total value of $1,269,800.00. Following the transaction, the director owned 11,183 shares in the company, valued at $1,420,017.34. This represents a 47.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 708,565 shares of company stock valued at $90,556,597 in the last three months. Company insiders own 5.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on GH shares. Royal Bank Of Canada initiated coverage on Guardant Health in a report on Thursday, June 11th. They set an “outperform” rating and a $185.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Guardant Health in a research note on Friday, July 17th. Sanford C. Bernstein upped their price objective on shares of Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, July 2nd. Evercore reiterated an “outperform” rating and issued a $200.00 target price on shares of Guardant Health in a research note on Monday, July 6th. Finally, Mizuho lifted their target price on shares of Guardant Health from $135.00 to $175.00 and gave the stock an “outperform” rating in a report on Monday, June 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $160.04.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.